Health

Add as a preferred source on Google

AstraZeneca’s Sone-Ve Enters Expedited FDA Review for Advanced Gastric Cancers

The application covers sonesitatug vedotin, also known as Sone-Ve, for certain patients with advanced gastric and related cancers.

Updated 1 min read
The Food and Drug Administration campus stands in Silver Spring, Maryland, under an overcast sky. / EconoTimes.ai
The Food and Drug Administration campus stands in Silver Spring, Maryland, under an overcast sky. / EconoTimes.ai

AstraZeneca said the U.S. Food and Drug Administration (FDA) accepted its application for sonesitatug vedotin, known as Sone-Ve, and granted it priority review on Nov. 19.

The application covers certain patients with advanced gastric and related cancers, according to AstraZeneca.

Related articles

View all